A citation-based method for searching scientific literature

B Moriyama, A Owusu Obeng, J Barbarino, S R Penzak, S A Henning, S A Scott, Jag Agúndez, J R Wingard, H L McLeod, T E Klein, S J Cross, K E Caudle, T J Walsh. Clin Pharmacol Ther 2017
Times Cited: 124







List of co-cited articles
574 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
J K Hicks, J R Bishop, K Sangkuhl, D J Müller, Y Ji, S G Leckband, J S Leeder, R L Graham, D L Chiulli, A LLerena,[...]. Clin Pharmacol Ther 2015
401
36

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.
S A Scott, K Sangkuhl, C M Stein, J-S Hulot, J L Mega, D M Roden, T E Klein, M S Sabatine, J A Johnson, A R Shuldiner. Clin Pharmacol Ther 2013
536
29

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.
J K Hicks, K Sangkuhl, J J Swen, V L Ellingrod, D J Müller, K Shimoda, J R Bishop, E D Kharasch, T C Skaar, A Gaedigk,[...]. Clin Pharmacol Ther 2017
206
29

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.
K A Birdwell, B Decker, J M Barbarino, J F Peterson, C M Stein, W Sadee, D Wang, A A Vinks, Y He, J J Swen,[...]. Clin Pharmacol Ther 2015
256
25

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
J A Johnson, K E Caudle, L Gong, M Whirl-Carrillo, C M Stein, S A Scott, M T Lee, B F Gage, S E Kimmel, M A Perera,[...]. Clin Pharmacol Ther 2017
238
22

Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron.
G C Bell, K E Caudle, M Whirl-Carrillo, R J Gordon, K Hikino, C A Prows, A Gaedigk, Jag Agundez, S Sadhasivam, T E Klein,[...]. Clin Pharmacol Ther 2017
77
28

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.
Thomas F Patterson, George R Thompson, David W Denning, Jay A Fishman, Susan Hadley, Raoul Herbrecht, Dimitrios P Kontoyiannis, Kieren A Marr, Vicki A Morrison, M Hong Nguyen,[...]. Clin Infect Dis 2016
941
20

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.
K R Crews, A Gaedigk, H M Dunnenberger, J S Leeder, T E Klein, K E Caudle, C E Haidar, D D Shen, J T Callaghan, S Sadhasivam,[...]. Clin Pharmacol Ther 2014
369
20

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
Matthew P Goetz, Katrin Sangkuhl, Henk-Jan Guchelaar, Matthias Schwab, Michael Province, Michelle Whirl-Carrillo, W Fraser Symmans, Howard L McLeod, Mark J Ratain, Hitoshi Zembutsu,[...]. Clin Pharmacol Ther 2018
122
19

Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.
Jacob T Brown, Jeffrey R Bishop, Katrin Sangkuhl, Erika L Nurmi, Daniel J Mueller, Jean C Dinh, Andrea Gaedigk, Teri E Klein, Kelly E Caudle, James T McCracken,[...]. Clin Pharmacol Ther 2019
51
35

CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?
Aniwaa Owusu Obeng, Eric F Egelund, Abdullah Alsultan, Charles A Peloquin, Julie A Johnson. Pharmacotherapy 2014
71
23

Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC).
Kelly E Caudle, Henry M Dunnenberger, Robert R Freimuth, Josh F Peterson, Jonathan D Burlison, Michelle Whirl-Carrillo, Stuart A Scott, Heidi L Rehm, Marc S Williams, Teri E Klein,[...]. Genet Med 2017
207
17

Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.
K E Caudle, A E Rettie, M Whirl-Carrillo, L H Smith, S Mintzer, M T M Lee, T E Klein, J T Callaghan. Clin Pharmacol Ther 2014
136
17

Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.
Michael J Dolton, John E Ray, Sharon C-A Chen, Kingsley Ng, Lisa G Pont, Andrew J McLachlan. Antimicrob Agents Chemother 2012
187
16


Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update.
Mary V Relling, Matthias Schwab, Michelle Whirl-Carrillo, Guilherme Suarez-Kurtz, Ching-Hon Pui, Charles M Stein, Ann M Moyer, William E Evans, Teri E Klein, Federico Guillermo Antillon-Klussmann,[...]. Clin Pharmacol Ther 2019
151
16

Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.
Fabien Lamoureux, Thomas Duflot, Jean-Baptiste Woillard, David Metsu, Tony Pereira, Patricia Compagnon, Hélène Morisse-Pradier, Mona El Kholy, Luc Thiberville, Jana Stojanova,[...]. Int J Antimicrob Agents 2016
45
33

Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.
Kelly E Caudle, Teri E Klein, James M Hoffman, Daniel J Muller, Michelle Whirl-Carrillo, Li Gong, Ellen M McDonagh, Katrin Sangkuhl, Caroline F Thorn, Matthias Schwab,[...]. Curr Drug Metab 2014
204
15

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Andres Pascual, Thierry Calandra, Saskia Bolay, Thierry Buclin, Jacques Bille, Oscar Marchetti. Clin Infect Dis 2008
568
15

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.
H Ruth Ashbee, Rosemary A Barnes, Elizabeth M Johnson, Malcolm D Richardson, Rebecca Gorton, William W Hope. J Antimicrob Chemother 2014
309
14

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.
L B Ramsey, S G Johnson, K E Caudle, C E Haidar, D Voora, R A Wilke, W D Maxwell, H L McLeod, R M Krauss, D M Roden,[...]. Clin Pharmacol Ther 2014
212
14

CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.
Johanna Weiss, Magdalena Maria Ten Hoevel, Jürgen Burhenne, Ingeborg Walter-Sack, Michael Marcus Hoffmann, Jens Rengelshausen, Walter E Haefeli, Gerd Mikus. J Clin Pharmacol 2009
132
14

Pharmacokinetic/pharmacodynamic profile of voriconazole.
Ursula Theuretzbacher, Franziska Ihle, Hartmut Derendorf. Clin Pharmacokinet 2006
267
14

Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
Issam S Hamadeh, Kenneth P Klinker, Samuel J Borgert, Ashley I Richards, Wenhui Li, Naveen Mangal, John W Hiemenz, Stephan Schmidt, Taimour Y Langaee, Charles A Peloquin,[...]. Pharmacogenet Genomics 2017
22
59

Pharmacogenetics: from bench to byte--an update of guidelines.
J J Swen, M Nijenhuis, A de Boer, L Grandia, A H Maitland-van der Zee, H Mulder, G A P J M Rongen, R H N van Schaik, T Schalekamp, D J Touw,[...]. Clin Pharmacol Ther 2011
576
13

Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults.
Naveen Mangal, Issam S Hamadeh, Meghan J Arwood, Larisa H Cavallari, Tanay S Samant, Kenneth P Klinker, Jurgen Bulitta, Stephan Schmidt. Clin Pharmacol Ther 2018
20
60

Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.
Henry M Dunnenberger, Kristine R Crews, James M Hoffman, Kelly E Caudle, Ulrich Broeckel, Scott C Howard, Robert J Hunkler, Teri E Klein, William E Evans, Mary V Relling. Annu Rev Pharmacol Toxicol 2015
256
12

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.
Ursula Amstutz, Linda M Henricks, Steven M Offer, Julia Barbarino, Jan H M Schellens, Jesse J Swen, Teri E Klein, Howard L McLeod, Kelly E Caudle, Robert B Diasio,[...]. Clin Pharmacol Ther 2018
162
12

Pharmacogenomics knowledge for personalized medicine.
M Whirl-Carrillo, E M McDonagh, J M Hebert, L Gong, K Sangkuhl, C F Thorn, R B Altman, T E Klein. Clin Pharmacol Ther 2012
900
12

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.
Katherine N Theken, Craig R Lee, Li Gong, Kelly E Caudle, Christine M Formea, Andrea Gaedigk, Teri E Klein, José A G Agúndez, Tilo Grosser. Clin Pharmacol Ther 2020
46
26

Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections.
Taotao Wang, Huifang Zhu, Jinyao Sun, Xiaoliang Cheng, Jiao Xie, Haiyan Dong, Limei Chen, Xue Wang, Jianfeng Xing, Yalin Dong. Int J Antimicrob Agents 2014
55
20

Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.
Ina Scholz, Heike Oberwittler, Klaus-Dieter Riedel, Jürgen Burhenne, Johanna Weiss, Walter E Haefeli, Gerd Mikus. Br J Clin Pharmacol 2009
114
11

Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers.
SeungHwan Lee, Bo-Hyung Kim, Won-Seok Nam, Seo Hyun Yoon, Joo-Youn Cho, Sang-Goo Shin, In-Jin Jang, Kyung-Sang Yu. J Clin Pharmacol 2012
62
17

Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients.
Xiao-Bin Lin, Zi-Wei Li, Miao Yan, Bi-Kui Zhang, Wu Liang, Feng Wang, Ping Xu, Da-Xiong Xiang, Xu-Biao Xie, Shao-Jie Yu,[...]. Br J Clin Pharmacol 2018
27
40

Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.
Taotao Wang, Siying Chen, Jinyue Sun, Jiangxia Cai, Xiaoliang Cheng, Haiyan Dong, Xue Wang, Jianfeng Xing, Weihua Dong, Hongping Yao,[...]. J Antimicrob Chemother 2014
48
22

In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3.
Souzan B Yanni, Pieter P Annaert, Patrick Augustijns, Joseph G Ibrahim, Daniel K Benjamin, Dhiren R Thakker. Drug Metab Dispos 2010
84
13

Voriconazole metabolism is influenced by severe inflammation: a prospective study.
Anette Veringa, Mendy Ter Avest, Lambert F R Span, Edwin R van den Heuvel, Daan J Touw, Jan G Zijlstra, Jos G W Kosterink, Tjip S van der Werf, Jan-Willem C Alffenaar. J Antimicrob Chemother 2017
56
17


Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis.
Haiying Jin, Tiansheng Wang, Bonnie A Falcione, Keith M Olsen, Ken Chen, Huilin Tang, John Hui, Suodi Zhai. J Antimicrob Chemother 2016
54
18


Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.
J Kevin Hicks, Kristine R Crews, Patricia Flynn, Cyrine E Haidar, Calvin C Daniels, Wenjian Yang, John C Panetta, Deqing Pei, Jeffrey R Scott, Alejandro R Molinelli,[...]. Pharmacogenomics 2014
36
27

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.
R S Gammal, M H Court, C E Haidar, O F Iwuchukwu, A H Gaur, M Alvarellos, C Guillemette, J L Lennox, M Whirl-Carrillo, S S Brummel,[...]. Clin Pharmacol Ther 2016
79
12

Pharmacogenomics in the clinic.
Mary V Relling, William E Evans. Nature 2015
355
10

Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole.
H-R He, J-Y Sun, X-D Ren, T-T Wang, Y-J Zhai, S-Y Chen, Y-L Dong, J Lu. Eur J Clin Microbiol Infect Dis 2015
30
30

Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.
Zi-Wei Li, Feng-Hua Peng, Miao Yan, Wu Liang, Xiao-Lei Liu, Yan-Qin Wu, Xiao-Bin Lin, Sheng-Lan Tan, Feng Wang, Ping Xu,[...]. Ther Drug Monit 2017
23
39

Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped.
E Gautier-Veyret, X Fonrose, F Stanke-Labesque. Clin Pharmacol Ther 2017
13
69

Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole.
Fang Qi, Liqin Zhu, Na Li, Tingyue Ge, Gaoqi Xu, Shasha Liao. Int J Antimicrob Agents 2017
33
27

Pharmacogenomics of the triazole antifungal agent voriconazole.
Gerd Mikus, Ina Maria Scholz, Johanna Weiss. Pharmacogenomics 2011
49
18

The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.
Wan Beom Park, Nak-Hyun Kim, Kye-Hyung Kim, Seung Hwan Lee, Won-Seok Nam, Seo Hyun Yoon, Kyoung-Ho Song, Pyoeng Gyun Choe, Nam Joong Kim, In-Jin Jang,[...]. Clin Infect Dis 2012
225
9

Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
Andres Pascual, Chantal Csajka, Thierry Buclin, Saskia Bolay, Jacques Bille, Thierry Calandra, Oscar Marchetti. Clin Infect Dis 2012
130
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.